{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:59Z","timestamp":1786979939419,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006302","name":"Universidad de Alcal\u00e1","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006302","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The burden disease before allogeneic transplantation (HSCT) or the early post-transplant minimal residual disease (MRD) are both predictive parameters for relapse and post-HSCT survival in acute myeloid leukemia (AML). Nonetheless, the combination of both can provide more accurate information to identify high risk patients. To analyze the impact of pre-HSCT disease burden (MRD- vs. MRD\u2009+\u2009vs. active disease (AD), the early post-transplant MRD (posMRD\u2009+\u2009vs. posMRD-), and the combination of both pre- and post-HSCT disease status of the post-HSCT outcomes in AML patients. We retrospectively analyzed 173 patients with AML who underwent HSCT in a single institution, patients were classified according to pre-HSCT disease status, and post-HSCT MRD. MRD was measured by multiparameter flow cytometry using a cut-off of 0.1% for MRD+. The post-HSCT outcomes were analyzed based on the pre-transplant status, post-transplant status, and by combining both parameters. Patients with AD and MRD\u2009+\u2009before HSCT had worse 3y-event free (EFS) and overall survival (OS) than MRD- patients, due to a higher cumulative incidence of relapse (CIR). Also, patients with posMRD\u2009+\u2009had worse outcomes than posMRD- group. In the combined analysis, patient with MRD-\/posMRD- had the best EFS and OS (3y-EFS 66.5%, 3y-OS 70.0%). Patients with MRD+\/posMRD- have worse prognosis (3y-EFS 39.0%, 3y-OS 54.0%) and specially the group with AD\/MRD- (3y-EFS 13.5%, 3y-OS 22.0%) and posMRD\u2009+\u2009regardless pre-HSCT disease status(3y-EFS 26.5%, 3y-OS 28.0%) had dismal OS and EFS. The combination of pre-HSCT disease burden and post-HSCT MRD measurements help us for identifying high-risk subgroups. Any level of pre-transplant disease (MRD+, and especially patients with active AD) is a risk factor, even when MRD- was achieved post-transplant. Patients with post-transplant MRD\u2009+\u2009also had an adverse prognosis. These should be target groups for implementing tailored pre- and post-transplant strategies to improve outcomes.<\/jats:p>","DOI":"10.1007\/s00277-025-06325-x","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:08:50Z","timestamp":1745557730000},"page":"2469-2481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination of disease burden before allogeneic transplantation and early post-transplant minimal residual disease predicts survival in patients with acute myeloid leukemia"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2881-161X","authenticated-orcid":false,"given":"Claudia N\u00fa\u00f1ez-Torr\u00f3n","family":"Stock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Jim\u00e9nez","family":"Chill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara L\u00f3pez","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Mart\u00edn","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Marquet","family":"Palomanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Piris","family":"Villaespesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro Luna","family":"de Abia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto Rold\u00e1n","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eulalia Rodr\u00edguez","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabelle Chinea","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn Garc\u00eda","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma Moreno","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier L\u00f3pez","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar Herrera","family":"Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"issue":"1","key":"6325_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/bjh.16355","volume":"188","author":"J Loke","year":"2020","unstructured":"Loke J, Malladi R, Moss P, Craddock C (2020) The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol 188(1):129\u2013146. https:\/\/doi.org\/10.1111\/bjh.16355","journal-title":"Br J Haematol"},{"issue":"4","key":"6325_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/hon.3160","volume":"41","author":"C N\u00fa\u00f1ez-Torr\u00f3n Stock","year":"2023","unstructured":"N\u00fa\u00f1ez-Torr\u00f3n Stock C, Jim\u00e9nez Chill\u00f3n C, Mart\u00edn Moro F et al (2023) Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de Novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry. Hematol Oncol 41(4):753\u2013761. https:\/\/doi.org\/10.1002\/hon.3160","journal-title":"Hematol Oncol"},{"key":"6325_CR3","doi-asserted-by":"publisher","first-page":"1394648","DOI":"10.3389\/fonc.2024.1394648","volume":"14","author":"C N\u00fa\u00f1ez-Torr\u00f3n Stock","year":"2024","unstructured":"N\u00fa\u00f1ez-Torr\u00f3n Stock C, Jim\u00e9nez Chill\u00f3n C, Mart\u00edn Moro F et al (2024) Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia. Front Oncol 14:1394648. https:\/\/doi.org\/10.3389\/fonc.2024.1394648","journal-title":"Front Oncol"},{"issue":"5","key":"6325_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2016.159343","volume":"102","author":"SA Buckley","year":"2017","unstructured":"Buckley SA, Wood BL, Othus M et al (2017) Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica 102(5):865\u2013873. https:\/\/doi.org\/10.3324\/haematol.2016.159343","journal-title":"Haematologica"},{"issue":"4","key":"6325_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41408-021-00471-x","volume":"11","author":"M Jentzsch","year":"2021","unstructured":"Jentzsch M, Grimm J, Bill M et al (2021) Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation. Blood Cancer J 11(4):80. https:\/\/doi.org\/10.1038\/s41408-021-00471-x","journal-title":"Blood Cancer J"},{"issue":"1","key":"6325_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbmt.2005.06.004","volume":"12","author":"W Blum","year":"2006","unstructured":"Blum W, Bolwell BJ, Phillips G et al (2006) High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol Blood Marrow Transpl 12(1):61\u201367. https:\/\/doi.org\/10.1016\/j.bbmt.2005.06.004","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"6325_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","volume":"34","author":"D Araki","year":"2016","unstructured":"Araki D, Wood BL, Othus M et al (2016) Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual Disease-Based definition of complete remission?? J Clin Oncol 34(4):329\u2013336. https:\/\/doi.org\/10.1200\/JCO.2015.63.3826","journal-title":"J Clin Oncol"},{"issue":"8","key":"6325_CR8","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.leukres.2012.04.005","volume":"36","author":"T Miyazaki","year":"2012","unstructured":"Miyazaki T, Fujita H, Fujimaki K et al (2012) Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia. Leuk Res 36(8):998\u20131003. https:\/\/doi.org\/10.1016\/j.leukres.2012.04.005","journal-title":"Leuk Res"},{"issue":"1","key":"6325_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12967-024-05114-w","volume":"22","author":"W Chen","year":"2024","unstructured":"Chen W, Huang J, Zhao Y et al (2024) Measurable residual disease monitoring by DdPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML\/MDS: a multicenter retrospective study. J Transl Med 22(1):410. https:\/\/doi.org\/10.1186\/s12967-024-05114-w","journal-title":"J Transl Med"},{"issue":"12","key":"6325_CR10","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, Middeke JM, Sockel K et al (2018) Measurable residual disease-guided treatment with Azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol 19(12):1668\u20131679. https:\/\/doi.org\/10.1016\/S1470-2045(18)30580-1","journal-title":"Lancet Oncol"},{"issue":"14","key":"6325_CR11","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1182\/bloodadvances.2022009493","volume":"7","author":"J Loke","year":"2023","unstructured":"Loke J, McCarthy N, Jackson A et al (2023) Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML\/MDS. Blood Adv 7(14):3666\u20133676. https:\/\/doi.org\/10.1182\/bloodadvances.2022009493","journal-title":"Blood Adv"},{"key":"6325_CR12","doi-asserted-by":"publisher","first-page":"994366","DOI":"10.3389\/fonc.2022.994366","volume":"12","author":"P Chiusolo","year":"2022","unstructured":"Chiusolo P, Metafuni E, Minnella G et al (2022) Day\u2009+\u200960 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients. Front Oncol 12:994366. https:\/\/doi.org\/10.3389\/fonc.2022.994366","journal-title":"Front Oncol"},{"issue":"3","key":"6325_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ajh.21340","volume":"84","author":"M D\u00edez-Campelo","year":"2009","unstructured":"D\u00edez-Campelo M, P\u00e9rez-Sim\u00f3n JA, P\u00e9rez J et al (2009) Minimal residual disease monitoring after allogeneic transplantation May help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol 84(3):149\u2013152. https:\/\/doi.org\/10.1002\/ajh.21340","journal-title":"Am J Hematol"},{"issue":"7","key":"6325_CR14","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.bbmt.2018.02.003","volume":"24","author":"MV Shah","year":"2018","unstructured":"Shah MV, Jorgensen JL, Saliba RM et al (2018) Early Post-Transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia. Biol Blood Marrow Transpl 24(7):1514\u20131520. https:\/\/doi.org\/10.1016\/j.bbmt.2018.02.003","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"6325_CR15","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","volume":"5","author":"M Heuser","year":"2021","unstructured":"Heuser M, Heida B, B\u00fcttner K et al (2021) Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv 5(9):2294\u20132304. https:\/\/doi.org\/10.1182\/bloodadvances.2021004367","journal-title":"Blood Adv"},{"issue":"3","key":"6325_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/bjh.14340","volume":"180","author":"FF Tang","year":"2018","unstructured":"Tang FF, Xu LP, Zhang XH et al (2018) Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic Haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia. Br J Haematol 180(3):448\u2013451. https:\/\/doi.org\/10.1111\/bjh.14340","journal-title":"Br J Haematol"},{"issue":"1","key":"6325_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12885-021-09051-5","volume":"22","author":"J Kong","year":"2022","unstructured":"Kong J, Gao MG, Qin YZ et al (2022) Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer 22(1):11. https:\/\/doi.org\/10.1186\/s12885-021-09051-5","journal-title":"BMC Cancer"},{"issue":"5","key":"6325_CR18","first-page":"267","volume":"28","author":"E Klyuchnikov","year":"2022","unstructured":"Klyuchnikov E, Badbaran A, Massoud R et al (2022) Post-Transplantation multicolored flow Cytometry-Minimal residual disease status on day 100 predicts outcomes for patients with refractory acute myeloid leukemia. Transpl Cell Ther 28(5):267..e1-267.e7","journal-title":"Transpl Cell Ther"},{"issue":"15","key":"6325_CR19","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","volume":"132","author":"T Kim","year":"2018","unstructured":"Kim T, Moon JH, Ahn JS et al (2018) Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. Blood 132(15):1604\u20131613. https:\/\/doi.org\/10.1182\/blood-2018-04-848028","journal-title":"Blood"},{"issue":"2","key":"6325_CR20","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3892\/etm.2017.5547","volume":"15","author":"Y Hao","year":"2018","unstructured":"Hao Y, Cheng Y, Wu Q, Zhang A, Jiang X, Xu X (2018) Combined usage of Wilms\u2019 tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation. Exp Ther Med 15(2):1403\u20131409. https:\/\/doi.org\/10.3892\/etm.2017.5547","journal-title":"Exp Ther Med"},{"issue":"11","key":"6325_CR21","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1182\/blood.2021014804","volume":"139","author":"G Paras","year":"2022","unstructured":"Paras G, Morsink LM, Othus M et al (2022) Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood 139(11):1694\u20131706. https:\/\/doi.org\/10.1182\/blood.2021014804","journal-title":"Blood"},{"issue":"3","key":"6325_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.beha.2013.10.008","volume":"26","author":"FR Appelbaum","year":"2013","unstructured":"Appelbaum FR (2013) Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Best Pract Res Clin Haematol 26(3):279\u2013284. https:\/\/doi.org\/10.1016\/j.beha.2013.10.008","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"6325_CR23","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/leu.2016.46","volume":"30","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Othus M, Araki D et al (2016) Pre- and post-transplant quantification of measurable (\u2018minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia 30(7):1456\u20131464. https:\/\/doi.org\/10.1038\/leu.2016.46","journal-title":"Leukemia"},{"issue":"6","key":"6325_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-021-00500-9","volume":"11","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Kim Y, Kang D et al (2021) Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Blood Cancer J 11(6):109. https:\/\/doi.org\/10.1038\/s41408-021-00500-9","journal-title":"Blood Cancer J"},{"issue":"20","key":"6325_CR25","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"4","key":"6325_CR26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"26","key":"6325_CR27","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ et al (2021) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party. Blood 138(26):2753\u20132767. https:\/\/doi.org\/10.1182\/blood.2021013626","journal-title":"Blood"},{"key":"6325_CR28","unstructured":"Carreras ERMZIVD (2016) Manual de trasplante hematopoy\u00e9tico. 5th ed. Spain"},{"issue":"24","key":"6325_CR29","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, International Working Group for Diagnosis et al (2003) Standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642\u20134649. https:\/\/doi.org\/10.1200\/JCO.2003.04.036","journal-title":"J Clin Oncol"},{"issue":"7","key":"6325_CR30","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41409-023-01961-1","volume":"58","author":"I Abou Dalle","year":"2023","unstructured":"Abou Dalle I, Labopin M, Kr\u00f6ger N et al (2023) Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the acute leukemia working party of the European society for blood and marrow transplantation. Bone Marrow Transpl 58(7):784\u2013790. https:\/\/doi.org\/10.1038\/s41409-023-01961-1","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"6325_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/bmt.2014.9","volume":"49","author":"C Anthias","year":"2014","unstructured":"Anthias C, Dignan FL, Morilla R et al (2014) Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic Hemopoietic SCT in AML. Bone Marrow Transpl 49(5):679\u2013683. https:\/\/doi.org\/10.1038\/bmt.2014.9","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"6325_CR32","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3390\/cancers15051609","volume":"15","author":"T Caballero-Vel\u00e1zquez","year":"2023","unstructured":"Caballero-Vel\u00e1zquez T, P\u00e9rez-L\u00f3pez O, Yeguas Bermejo A et al (2023) Prognostic value of measurable residual disease in patients with AML undergoing HSCT: A multicenter study. Cancers (Basel) 15(5):1609. https:\/\/doi.org\/10.3390\/cancers15051609","journal-title":"Cancers (Basel)"},{"issue":"3","key":"6325_CR33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/bjh.15540","volume":"183","author":"J Canaani","year":"2018","unstructured":"Canaani J, Labopin M, Huang XJ et al (2018) Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the acute leukaemia working party (ALWP) of the European society for blood and marrow transplantation (EBMT). Br J Haematol 183(3):411\u2013420. https:\/\/doi.org\/10.1111\/bjh.15540","journal-title":"Br J Haematol"},{"issue":"7","key":"6325_CR34","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1200\/JCO.20.02308","volume":"39","author":"C Craddock","year":"2021","unstructured":"Craddock C, Jackson A, Loke J et al (2021) Augmented Reduced-Intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol 39(7):768\u2013778. https:\/\/doi.org\/10.1200\/JCO.20.02308","journal-title":"J Clin Oncol"},{"issue":"7","key":"6325_CR35","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","volume":"23","author":"BM Getta","year":"2017","unstructured":"Getta BM, Devlin SM, Levine RL et al (2017) Multicolor flow cytometry and multigene Next-Generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation. Biol Blood Marrow Transpl 23(7):1064\u20131071. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"6325_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-021-00479-3","volume":"11","author":"MH Gilleece","year":"2021","unstructured":"Gilleece MH, Shimoni A, Labopin M et al (2021) Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. Blood Cancer J 11(5):88. https:\/\/doi.org\/10.1038\/s41408-021-00479-3","journal-title":"Blood Cancer J"},{"issue":"12","key":"6325_CR37","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G et al (2020) Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol 38(12):1273\u20131283. https:\/\/doi.org\/10.1200\/JCO.19.03011","journal-title":"J Clin Oncol"},{"issue":"10","key":"6325_CR38","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/s41409-022-01748-w","volume":"57","author":"E Maffini","year":"2022","unstructured":"Maffini E, Labopin M, Beelen DW et al (2022) Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A study from the acute leukemia working party (ALWP) of the European society for blood and marrow transplantation (EBMT). Bone Marrow Transpl 57(10):1556\u20131563. https:\/\/doi.org\/10.1038\/s41409-022-01748-w","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"6325_CR39","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3390\/cancers12092339","volume":"12","author":"LM Morsink","year":"2020","unstructured":"Morsink LM, Sandmaier BM, Othus M et al (2020) Conditioning intensity, Pre-Transplant flow cytometric measurable residual disease, and outcome in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Cancers (Basel) 12(9):2339. https:\/\/doi.org\/10.3390\/cancers12092339","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6325_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3324\/haematol.2016.144253","volume":"102","author":"B Oran","year":"2017","unstructured":"Oran B, Jorgensen JL, Marin D et al (2017) Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica 102(1):110\u2013117. https:\/\/doi.org\/10.3324\/haematol.2016.144253","journal-title":"Haematologica"},{"issue":"1","key":"6325_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3324\/haematol.2022.281631","volume":"108","author":"E Rodr\u00edguez-Arbol\u00ed","year":"2023","unstructured":"Rodr\u00edguez-Arbol\u00ed E, Othus M, Orvain C et al (2023) Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Haematologica 108(1):273\u2013277. https:\/\/doi.org\/10.3324\/haematol.2022.281631","journal-title":"Haematologica"},{"issue":"12","key":"6325_CR42","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C et al (2020) Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: A systematic review and Meta-analysis. JAMA Oncol 6(12):1890\u20131899. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4600","journal-title":"JAMA Oncol"},{"issue":"16","key":"6325_CR43","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A et al (2018) Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 132(16):1703\u20131713. https:\/\/doi.org\/10.1182\/blood-2018-02-829911","journal-title":"Blood"},{"issue":"1","key":"6325_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/leu.2014.173","volume":"29","author":"RB Walter","year":"2015","unstructured":"Walter RB, Gyurkocza B, Storer BE et al (2015) Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 29(1):137\u2013144. https:\/\/doi.org\/10.1038\/leu.2014.173","journal-title":"Leukemia"},{"issue":"10","key":"6325_CR45","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","volume":"122","author":"RB Walter","year":"2013","unstructured":"Walter RB, Buckley SA, Pagel JM et al (2013) Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 122(10):1813\u20131821. https:\/\/doi.org\/10.1182\/blood-2013-06-506725","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06325-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06325-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06325-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T23:14:23Z","timestamp":1746400463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06325-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6325"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06325-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}}]}}